FTC Letters On Ambien CR Agreements Are "Educational" And A "Warning" For Industry
This article was originally published in The Pink Sheet Daily
Executive Summary
FTC's rebukes Sanofi, Watson and Synthon for failing to report agreements related to generic challenges of the insomnia drug, but Bureau of Competition Director Feinstein notes that the Commission is not seeking to fine the firms.